About Nucleolar protein 9
Nucleolar protein 9 (NOP9) is a protein
from Homo sapiens identified by UniProt accession
Q86U38, 636 residues long.
MolForge cross-references it against 0 known binders and
5 disease associations.
Target properties
| Protein name | Nucleolar protein 9 |
|---|
| UniProt accession | Q86U38 |
|---|
| Gene | NOP9 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 636 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (5)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.30
- language impairment · score 0.25
- lysosomal storage disease · score 0.15
- appendicular lean mass · score 0.03
- body height · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q86U38-F1 | alphafold | PREDICTED | 86.27 | — |
Amino-acid sequence (636 residues)
MGQGPRSPHK VGRRFPAGGK RGRGAKGSGR PLPGRKRQPW PPPDGRSEPA PDSHPHLSPE ALGYFRRALS ALKEAPETGE ERDLMVHNIM KEVETQALAL STNRTGSEML QELLGFSPLK PLCRVWAALR SNLRTVACHR CGVHVLQSAL LQLPRLLGSA AEEEEEEEED GKDGPTETLE ELVLGLAAEV CDDFLVYCGD THGSFVVRTL LQVLGGTILE SERARPRGSQ SSEAQKTPAQ ECKPADFEVP ETFLNRLQDL SSSFLKDIAV FITDKISSFC LQVALQVLHR KLPQFCAHLC NAVIGYLSTR GSSVDGSPLL LFLRDQTSSR LLEQVLLVLE PPRLQSLFEE HLQGQLQTLA AHPIANFPLQ RLLDAVTTPE LLSPVFEELS PVLEAVLAQG HPGVVIALVG ACRRVGAYQA KVLQLLLEAF HCAEPSSRQV ACVPLFATLM AYEVYYGLTE EEGAVPAEHQ VAMAAARALG DVTVLGSLLL QHLLHFSTPG LVLRSLGALT GPQLLSLAQS PAGSHVLDAI LTSPSVTRKL RRRVLQNLKG QYVALACSRH GSRVLDAIWS GAALRARKEI AAELGEQNQE LIRDPFGHHV ARNVALTTFL KRREAWEQQQ GAVAKRRRAL NSILED
Explore Nucleolar protein 9 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets